

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Carton for 10 ml and 20 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Metacam 5 mg/ml solution for injection for dogs
and cats Meloxicam

2. STATEMENT OF ACTIVE SUBSTANCES

Meloxicam 5 mg/ml

3. PHARMACEUTICAL FORM

Solution for injection

4. PACKAGE SIZES

10 ml
20 ml

5. TARGET SPECIES

Dogs and cats

6. INDICATIONS

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Dogs: Musculo-skeletal disorders: single subcutaneous injection.
Post-operative pain: single intravenous or subcutaneous injection.
Cats: Post-operative pain: single subcutaneous injection.

Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

9. SPECIAL WARNING(S), IF NECESSARY

Do not use in pregnant or lactating animals.

10. EXPIRY DATE

EXP. {month/year}
Once broached use within 28 days.

11. SPECIAL STORAGE CONDITIONS

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Vetmedica
GmbH 55216 Ingelheim/Rhein
GERMANY

16. MARKETING AUTHORISATION NUMBERS

EU/2/97/004/006 10 ml
EU/2/97/004/011 20 ml

17. MANUFACTURER'S BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Vial, 10 ml and 20 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Metacam 5 mg/ml solution for injection for dogs
and cats Meloxicam

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

Meloxicam 5 mg/ml

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

10 ml
20 ml

4. ROUTE(S) OF ADMINISTRATION

Dogs: IV or SC
Cats: SC

5. WITHDRAWAL PERIOD(S)

6. BATCH NUMBER

Lot {number}

7. EXPIRY DATE

EXP {month/year}
Once broached use within 28 days.

8. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

EU/2/97/004/014 12 x 50 ml
EU/2/97/004/015 12 x 100 ml
EU/2/97/004/032 6 x 250 ml

17. MANUFACTURER'S BATCH NUMBER
--

Lot {number}

B. PACKAGE LEAFLET

**PACKAGE LEAFLET:
Metacam 5 mg/ml solution for injection
for dogs and cats**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION
HOLDER AND OF THE MANUFACTURING AUTHORISATION
HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation
holder Boehringer
Ingelheim Vetmedica
GmbH 55216
Ingelheim/Rhein
GERMANY

Manufacturers responsible
for batch release Labiana
Life Sciences S.A.
Venus, 26
Can
Parellada
Industrial
08228
Terrassa,
Barcelona
SPAIN

KVP Pharma + Veterinär
Produkte GmbH
Projensdorfer Str. 324
24106 Kiel GERMANY

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Metacam 5 mg/ml solution for injection
for dogs and cats Meloxicam

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER
INGREDIENTS**

One ml
contains:
Meloxicam 5 mg
Ethanol 150 mg Clear yellow solution.

4. INDICATION(S)

Dogs:

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.

Cats:

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

5. CONTRAINDICATIONS

Do not use in pregnant or lactating animals.

Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in animals less than 6 weeks of age nor in cats of less than 2 kg.

6. ADVERSE REACTIONS

Typical adverse reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have very rarely been reported from post-marketing safety experience.

Very rare cases of haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported from post-marketing safety experience. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

Anaphylactoid reactions have been observed very rarely from post-marketing safety experience and should be treated symptomatically.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

7. TARGET SPECIES

Dogs and cats

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

Dosage for each species

Dogs: single administration of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg). Cats: single administration of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg).

Method and routes of administration Dogs:

Musculo-skeletal disorders: single subcutaneous injection.

Metacam 1.5 mg/ml oral suspension for dogs or Metacam 1 mg and 2.5 mg chewable tablets for dogs may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg body weight, 24 hours after administration of the injection.

Reduction of post-operative pain (over a period of 24 hours): single intravenous or subcutaneous injection before surgery, for example at the time of induction of anaesthesia.

Cats:

Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery: single subcutaneous injection before surgery, for example at the time of induction of anaesthesia.

9. ADVICE ON CORRECT ADMINISTRATION

Particular care should be taken with regard to the accuracy of dosing. Avoid introduction of contamination during use.

10. WITHDRAWAL PERIOD(S)

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions. Shelf life after first opening the container: 28 days.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle after EXP.

12. SPECIAL WARNING(S)

Special precautions for use in animals:

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. During anaesthesia, monitoring and fluid therapy should be considered as standard practice.

Special precautions to be taken by the person administering the veterinary medicinal product to animals: Accidental self-injection may give rise to pain.

People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental self-injection, seek medical advice immediately and show this package leaflet or the label to the physician.

This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.

Pregnancy and lactation:

See section "Contraindications".

Interaction with other medicinal products and other forms of interaction:

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Metacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided. In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration. When anaesthesia and NSAID are concomitantly administered, a risk for renal function cannot be excluded.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

Overdose (symptoms, emergency procedures, antidotes):

In case of overdose symptomatic treatment should be initiated.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

15. OTHER INFORMATION

10 ml or 20 ml injection vial.
Not all pack sizes may be marketed.